Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02041715 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802
A Phase 1 study, sponsored by Arbutus Biopharma Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02041715 is a Phase 1 study that was terminated before completion, run by Arbutus Biopharma Corporation. The registered enrollment target is 21 participants.
The verdict
NCT02041715, a Phase 1 study, was terminated before completion, sponsored by Arbutus Biopharma Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single ascending dose (SAD) study followed by a multiple-dose cohort in healthy male and female subjects.
Interventions
- DRUG Placebo
- DRUG TKM-100802 for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02041715
The ClinicalTrials.gov registry entry for NCT02041715 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arbutus Biopharma Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02041715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02041715 about?
NCT02041715 is a clinical study titled "Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802". Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single ascending dose (SAD) study followed by a multiple-dose cohort in healthy male and female subjects.
What is the current status of trial NCT02041715?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2014-01. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02041715?
The interventions under investigation include: Placebo (DRUG), TKM-100802 for Injection (DRUG).
Who is sponsoring clinical trial NCT02041715?
This trial is sponsored by Arbutus Biopharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.